Drug intelligence / Profile preview

ImmCelz

Development stage: Unknown
Lead developer: Creative Medical Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ImmCelz is a regenerative cell therapy developed by Creative Medical Technology Holdings (CMTH) using technology licensed from Jadi Cell. The therapy involves "reprogramming" a patient's own immune cells (or donor cells) ex vivo to enhance their regenerative and immunomodulatory properties. Specifically, it is designed to induce immunological tolerance by stimulating the expansion of T regulatory cells (Tregs) and increasing the production of Hepatocyte Growth Factor (HGF). ImmCelz is being investigated for a variety of indications, including the treatment of stroke, Type 1 Diabetes, heart disease, and the prevention of organ transplant rejection, with the goal of reducing reliance on chronic immunosuppression.

Brand names: ImmCelz
Other names: Supercharged Treg Biologic Immunotherapy

Beyond the preview

Go deeper on ImmCelz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmCelz.

Explore the full profile